Biodefense Market

Market Overview:

The global biodefense market size reached US$ 15.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 22.6 Billion by 2028, exhibiting a growth rate (CAGR) of 6.32% during 2023-2028.

Biodefense can be defined as the activity of preparing for, responding to and countering the acts of bioterrorism. A bioterrorism attack involves the deliberate release of bacteria, viruses and other pathogens that can cause chronic illnesses to humans, animals, agriculture and the environment. Biodefense involves various medical measures that are undertaken to protect individuals against biological threats, such as administering vaccinations and medicinal drugs, along with conducting research and various public health procedures. Biodefense products are commonly effective against anthrax, smallpox, botulism, radiation/nuclear disasters and other such catastrophes.

The growing threat of terrorism, coupled with continually rising tension between nations across the globe, is one of the key factors driving the growth of the market. Furthermore, the increasing defense expenditure by the governments of several nations to improve both internal and external security is also providing a boost to the market growth. In line with this, there is widespread adoption of innovative technologies, such as gene chips, for the detection of pathogens in the fields of nanotechnology, forensics and biodefense-related drug development. Additionally, government agencies are recognizing various chemical, biological, nuclear and radiological threats and are developing medical countermeasures to minimize the adverse effects of these attacks. Apart from this, there is an increasing awareness regarding synthetic biology for improving agricultural yields, which is also creating a positive impact on the market growth. Apart from these, due to the recent COVID-19 pandemic, there has been an increasing demand for medical measures and threat detection procedures, which is also providing a boost to the market growth. Other factors, including extensive research and development (R&D) in the field of biotechnology, along with the availability of advanced biothreat detection devices, are projected to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global biodefense market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on vaccine type, biothreat detection device and end-user.

Breakup by Vaccine Type:

• Anthrax
• Smallpox
• Botulism
• Others

Breakup by Biothreat Detection Device:

• Samplers
• Detectors/Triggering Devices
• Identifiers
• Assays
• Others
   

Breakup by End-User:

• Hospitals and Clinics
• Ambulatory Care Centers
• Others
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Achaogen Inc., Alnylam Pharmaceuticals Inc., Altimmune Inc. (PharmAthene Inc.), Bavarian Nordic A/S, Cleveland BioLabs Inc., Dynavax Technologies Corporation, Dynport Vaccine Company LLC (General Dynamics Corporation), Elusys Therapeutics Inc., Emergent Biosolutions Inc., Ichor Medical Systems Inc., Ology Bioservices Inc., SIGA Technologies, Inc., etc.

Report Coverage: